Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $75.81 USD
Change Today +0.60 / 0.80%
Volume 1.2M
DGX On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3 Giralda Farms

Madison, NJ 07940

United States

Phone: 973-520-2700

Fax:

dy of microscopic forms of life, including parasites, bacteria, viruses, fungi and other infectious agents); Oncology (the study of abnormal cell growth, including pre-cancerous conditions and cancer); Serology (a science dealing with body fluids and their analysis, including antibodies, proteins and other characteristics); and Toxicology (the study of chemicals and drugs and their intended and adverse effects on the body). The company provides its services through its network of major laboratories, anatomic pathology laboratories and rapid response laboratories. The company conducts complex and specialized testing, including molecular diagnostics, in its Quest Diagnostics Nichols Institute laboratory facilities and in other facilities, including Focus Diagnostics and Athena Diagnostics. The company also provides routine testing services, and inpatient anatomic pathology and medical director services, at hospital laboratories. Most of its services are provided under the Quest Diagnostics brand, but the company also provides services under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Solstas and Summit Health brands. International: The company provides diagnostic information services in markets outside the United States. The company has laboratory facilities in Gurgaon, India; Heston, England; Mexico City, Mexico; and San Juan, Puerto Rico. These laboratories support the provision of diagnostic information services in their local markets. Diagnostic Solutions Group In the Diagnostic Solutions group, the company offers various solutions for insurers, healthcare providers and others. The company is a provider of risk assessment services for the life insurance industry. The company also is a provider of testing for clinical trials. In addition, the company offers healthcare organizations and clinicians robust information technology solutions and diagnostic products. In addition, the company introduced approximately 60 new or enhanced disease area solutions, which are as follows: Cancer: The company introduced expanded pathology and blood test offerings to help identify and assess an individual's risk of Lynch syndrome, an inherited genetic disorder that increases the risk of colorectal and other cancers. The company introduced a new cancer test service based on the FDA-approved THxlD-BRAF test from bioMerieux. This test is a companion diagnostic for two treatments for melanoma. Based on its collaboration with Memorial Sloan Kettering Cancer Center, the company introduced OncoVantage, a solution to enable molecular characterization of solid tumors, to improve physicians' ability to treat patients with breast, prostate, colon, lung and various other solid tumors. The company introduced its BRCAvantagePlus solution, a suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA, as well as BRCA genes. The company introduced BRCAvantage Ashkenazi Jewish Screen with Reflex BRCAvantage comprehensive testing that makes it more convenient for physicians to order testing for patients of Ashkenazi descent. The company released testing for tamoxifen metabolites by mass spectrometry to aid physicians in treating breast cancer patients. Infectious Disease and Immunology The company developed and introduced tests for Hepatitis C Viral NS5 a/b genotypes, to detect resistance for new Hepatitis C therapies. The company enhanced the Hepatitis C Viral NS3 genotype assay to include simeprevir; and this assay might be used to detect boceprevir, telaprevir and simeprevir resistance-associated NS3 mutations in NS3 protease inhibitor treatment-experienced patients. The company developed and released molecular diagnostic tests for Influenza A/B & RSV; and these tests detect and differentiate human influenza A/B and RSV. The company developed and introduced an updated C difficile test; and this new test simultaneously detects C difficile glutamate dehydrogenase antigen and toxins A and B, conforming to testing guidelines. The company enhanced its chikungunya virus offering by developing and releasi

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $75.81 USD +0.60

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMerieux €98.06 EUR +0.84
Hologic Inc $33.99 USD +0.56
Laboratory Corp of America Holdings $126.93 USD +0.55
QIAGEN NV €22.90 EUR +0.004
Roper Industries Inc $169.92 USD -0.13
View Industry Companies
 

Industry Analysis

DGX

Industry Average

Valuation DGX Industry Range
Price/Earnings 21.7x
Price/Sales 1.5x
Price/Book 2.6x
Price/Cash Flow 18.1x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.